Iobenguane I-123

Last Updated: 02/24/2026

Need to find the closest trial?
Sort By Distance
Save trials for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
1 clinical trial found

    A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

    A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

    Who is this study for: Patients with Neuroblastoma, Ganglioneuroblastoma
    Enrollment Status: Recruiting
    Publish Date: December 22, 2025
    Intervention Type: Drug, Procedure, Biological, Radiation
    Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
    Study Phase: Phase 3

    Summary: This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Gi...

    Showing 1-1 of 1

    Last Updated: 02/24/2026